Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo.

Evidence for distinct human cancer stem cells (CSCs) remains contentious and the degree to which different cancer cells contribute to propagating malignancies in patients remains unexplored. In low- to intermediate-risk myelodysplastic syndromes (MDS), we establish the existence of rare multipotent...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs:	Woll, P, Kjällquist, U, Chowdhury, O, Doolittle, H, Wedge, D, Thongjuea, S, Erlandsson, R, Ngara, M, Anderson, K, Deng, Q, Mead, A, Stenson, L, Giustacchini, A, Duarte, S, Giannoulatou, E, Taylor, S, Karimi, M, Scharenberg, C, Mortera-Blanco, T, Macaulay, I, Clark, SA, Dybedal, I, Josefsen, D, Fenaux, P, Hokland, P, Holm, MS, Cazzola, M, Malcovati, L, Tauro, S, Bowen, D, Boultwood, J, Pellagatti, A, Pimanda, J, Unnikrishnan, A, Vyas, P, Göhring, G, Schlegelberger, B, Tobiasson, M, Kvalheim, G, Constantinescu, SN, Nerlov, C, Nilsson, L, Campbell, P, Sandberg, R, Papaemmanuil, E, Hellström-Lindberg, E, Linnarsson, S, Jacobsen, S
Formaat:	Journal article
Taal:	English
Gepubliceerd in:	Cell Press 2014

Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo.

Gelijkaardige items